my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
17-02-2010: immatics biotechnologies GmbH announced it has signed a collaboration with Cancer Research UK for the further development of immatics’ therapeutic cancer vaccine IMA950 in glioblastoma, the most aggressive form of brain cancer. Under the terms of the agreement, Cancer Research UK will sponsor and conduct a Phase I trial of IMA950 to be carried out at leading glioma research centres in the UK via its Drug Development Office. immatics will supply the drug IMA950 for the trial and also undertake immunomonitoring in the treated patients.
After the completion of the study, immatics will have an exclusive first right to take a license to the data for further development of IMA950. No financial details were disclosed.
Paul Higham, CEO of immatics said: “Cancer Research UK is a world-renowned cancer research organisation and we are delighted that through this collaboration we will be able to efficiently move our third therapeutic cancer vaccine into the clinic, highlighting the wide applicability and productivity of our XPRESIDENT™ technology platform.”
Dr Victoria John, head of clinical partnerships at Cancer Research UK’s Drug Development Office, said: “We’re very pleased to be taking on the next stage of this vaccine’s development. This form of glioma is very difficult to treat successfully and we hope this trial will help to establish if the immatics vaccine might offer another viable treatment option for people with this type of cancer.”
IMA950 is a therapeutic cancer vaccine generated through immatics’ proprietary XPRESIDENT™ technology. It consists of 11 tumour-associated peptides (TUMAPs) which the immatics platform selects on the basis of their natural presentation by tumour tissue, immunogenicity and their relevance to tumour function. This unique approach to rationally designed therapeutic vaccines which are a combination of multiple, highly relevant tumour peptides is at the core of all immatics’ clinical programmes.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
immatics appoints Peter Chambré as Chairman
immatics biotechnologies GmbH announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He wi ... more
Kidney Cancer Vaccine Successful in Clinical Trials
Researchers at the University of Tübingen and immatics biotechnologies GmbH – a start-up by Tübingen scientists – have published the results of two clinical studies using the kidney-cancer vaccine IMA901 in the latest edition of Nature Medicine. IMA901 is used to treat patients with cancer ... more
immatics wins 2012 TiE50 Award
immatics biotechnologies GmbH announced that it has been named a 2012 TiE50 winner. These awards recognize entrepreneurship, innovation and management excellence within the life sciences, software, internet, mobile and energy sectors. immatics was chosen from more than 2,100 technology sta ... more
immatics is developing cancer drugs that help to activate the self defense mechanisms of the human body. Our goal is to support patients and physicians with new options in the fight against various cancers. Our means are synthetic peptides that specifically activate specialized white blo ... more
New trial will investigate cancer-fighting properties of cannabinoid
Chemicals similar to those found in cannabis form the basis of a new drug that is being trialled in UK cancer patients for the first time by researchers at the Cancer Research UK and National Institute for Health Research (NIHR) Experimental Cancer Medicine Centre in Newcastle. The trial – ... more
immatics biotechnologies GmbH announced it has signed a collaboration with Cancer Research UK for the further development of immatics’ therapeutic cancer vaccine IMA950 in glioblastoma, the most aggressive form of brain cancer. Under the terms of the agreement, Cancer Research UK will spons ... more
Eppendorf Young Investigator Award 2008 for Dr. Simon Boulton
Dr. Simon Boulton of the London Research Institute (Clare Hall Laboratories, South Mimms, Hertfordshire) won the Eppendorf Young Investigator Award for his groundbreaking work on SPAR1, a newly discovered helicase. SPAR1 plays an important, controlling role in the repair of double-stranded ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
